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Abstract
Purpose: While animal models are widely used to investigate the development of restenosis in blood vessels following an
intervention, computational models offer another means for investigating this phenomenon. A computational model of the
response of a treated vessel would allow investigators to assess the effects of altering certain vessel- and stent-related
variables. The authors aimed to develop a novel computational model of restenosis development following an angioplasty
and bare-metal stent implantation in an atherosclerotic vessel using agent-based modeling techniques. The presented
model is intended to demonstrate the body’s response to the intervention and to explore how different vessel geometries
or stent arrangements may affect restenosis development.
Methods: The model was created on a two-dimensional grid space. It utilizes the post-procedural vessel lumen diameter
and stent information as its input parameters. The simulation starting point of the model is an atherosclerotic vessel after an
angioplasty and stent implantation procedure. The model subsequently generates the final lumen diameter, percent
change in lumen cross-sectional area, time to lumen diameter stabilization, and local concentrations of inflammatory
cytokines upon simulation completion. Simulation results were directly compared with the results from serial imaging
studies and cytokine levels studies in atherosclerotic patients from the relevant literature.
Results: The final lumen diameter results were all within one standard deviation of the mean lumen diameters reported in
the comparison studies. The overlapping-stent simulations yielded results that matched published trends. The cytokine
levels remained within the range of physiological levels throughout the simulations.
Conclusion: We developed a novel computational model that successfully simulated the development of restenosis in a
blood vessel following an angioplasty and bare-metal stent deployment based on the characteristics of the vessel cross-
section and stent. A further development of this model could ultimately be used as a predictive tool to depict patient
outcomes and inform treatment options.
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Introduction
In an atherosclerotic blood vessel, blood flow is restricted by the
accumulation of plaque, which causes the walls of the vessel to
become inflamed [1]. The subsequent narrowing of the lumen of
the blood vessel by the plaque causes ischemia, and vascular
intervention is usually required to compress the plaque and regain
the lumen area to restore blood flow [2]. According to a report
published recently, an estimated 492,000 patients underwent
percutaneous coronary intervention (PCI) procedures in 2010 in
the United States [3], and stents (drug-eluting stents and bare-
metal stents) were deployed in 454,000 of these patients (or
roughly 92% of all patients) during these PCI procedures [3].
Although the goal of a PCI intervention is to re-expand the lumen
of the target blood vessel, the body’s natural wound healing
response at the site of the intervention can cause a re-narrowing of
the treated vessel, or restenosis, which often counteracts what
would be an otherwise successful intervention [2,4]. Up to 60% of
such PCI and similar interventions to treat ischemic lesions fail
because of restenosis [2,5]. The ensuing target lesion revascular-
ization caused by in-stent restenosis can be severe and detrimental
to a patient’s recovery [6]. Some studies have shown that as many
as one-third of patients with in-stent restenosis developed
subsequent myocardial infarctions or unstable angina that
required the patient to be hospitalized [7].
Animal models such as rats, mice, rabbits, and pigs have been
used extensively to investigate the progression of restenosis in
stented arteries and have provided a wealth of insightful
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information about this complication in the past several decades
[8,9]. Nevertheless, because computational models are useful for
simulating situations that cannot be created in an animal and
permit fast and precise perturbations of the simulation environ-
ment, they are conducive to identifying the major effectors of the
process being simulated and present a viable alternative to animal
models. Agent-based modeling is a computational modeling
technique for simulating the actions and interactions of agents
(such as cytokines, cells, tissues, and organs) in an environment of
interest [10]. When agents interact with each other stochastically,
their aggregate behavior leads to complex, emergent phenomena
that represent the system as a whole. Agent-based models can
provide both numerical values and overall visual patterns in the
course of the simulations, which are typically very informative.
The model presented in this article was developed with the
NetLogo platform [11].
The rest of this article is broken into four sections: materials and
methods, results, discussion, and conclusions. The materials and
methods section presents the clinical events simulated, model
construction procedure, model interface, outputs, parameter
sensitivity analysis, and model validation procedures. The results
section describes the results from various simulations for a single
stent and overlapping stents, including quantitative values and
visual outputs. The discussion section provides detailed explana-
tion of the obtained results, limitations of the model, and plans for
further development of the model. The conclusion section includes
a brief summary of the model results and possible future directions.
Materials and Methods
A. Clinical Events Simulated
A normal coronary artery consists of three concentric layers,
from the innermost to the outermost, called the intima, media, and
adventitia. The intima is covered by a single layer of endothelial
cells (ECs); the media comprises mainly smooth muscle cells
(SMCs) and elastic tissues; and the adventitia is rich in fibroblasts
and connective tissues [1,2]. In the course of an inflammatory
reaction, platelets, neutrophils, and macrophages are
activated and recruited to the wound site. These cell types can
produce pro-inflammatory or anti-inflammatory cytokines, such as
TNF-a (tumor necrosis factor alpha) and TGF-b (transforming
growth factor beta) [1,12,13]. After an angioplasty and subsequent
stent deployment procedure, stent struts become part of the
artery and are therefore included in this model from the beginning
of simulation. These are the major contributors to restenosis
development and are represented by agents in this agent-based
model.
In addition to these major components, an atherosclerotic
coronary artery (the blood vessel simulated in this model) has a
lipid-rich core called plaque [14] between the intimal and medial
layers. At the interface of the intima and the plaque, SMCs and
elastic tissues may also be present. Depending on the thickness and
composition of this particular layer (sometimes referred to as a
‘‘fibrous cap’’ in the literature), the plaque can be stable or
vulnerable to breaking (plaque rupture) during the angioplasty and
stent-deployment procedure. Plaque rupture can lead to an intense
inflammatory reactions and be accompanied by an acute
thrombosis, and therefore requires a different therapeutic
approach for controlling acute inflammatory reactions and
thrombosis, such as administering anti-platelet drugs and anti-
inflammatory drugs [15–19]. The behavior of cells that contribute
to restenosis development is altered in the presence of such drugs
and is dependent on drug type and dosage. Because the goal of the
model is to elucidate how the cell types and cytokines of interest
contribute to in-stent restenosis development when drugs are not
present, it is assumed that there is no plaque rupture during the
angioplasty and stent procedure. The model solely simulates the
vessel’s and body’s response to the injuries created by the
angioplasty and stent procedure.
As a result, the processes simulated in the model are quite
similar to the typical wound healing following tissue injury [20].
The first phase of the wound healing response involves the
aggregation of platelets and the infiltration of inflammatory cells
(such as macrophages and neutrophils), followed by proliferation
and apoptosis of ECs and SMCs under the stimulation of
inflammatory cytokines (such as TGF-b and TNF-a) [21–23].
Inter-patient differences in the extent and rate of wound healing
are largely due to differences in physiological variables such as the
cytokine-dependent SMCs and ECs proliferation rates.
A holistic summary of the processes simulated in the model is
presented below. Prior to simulation initiation, SMCs and ECs are
injured during the angioplasty and stent procedure. The result of
this procedure is the starting point of the model simulation. Step
1: Exposure of the subendothelial matrix (SEM) and collagens as a
result of the endothelial cell damage immediately activates
circulating latent platelets [24]. Activated platelets aggregate to
form a growing thrombus and activate circulating latent platelets
upon contact [24]. Step 2: SMCs, ECs, and activated platelets
release anti-inflammatory cytokines such as TGF-b [25,26]. Step
3: Sufficient amounts of TGF-b trigger the recruitment of
monocytes and neutrophils to the wound site [27,28]. In vivo, this
recruitment is actually performed by the SEM, which releases
TGF-b and other chemoattractants to draw monocytes and
neutrophils to the wound site [29–31]. Monocytes migrate through
the thrombus [30] and mature into macrophages when they reach
the tissue [26,32]. Neutrophils form contact-based aggregates with
activated platelets and become integrated into the thrombus
[30,31,33]. Step 4: Monocytes, neutrophils, and macrophages
release pro-inflammatory cytokines such as TNF-a [34]. Step 5:
Both pro- and anti-inflammatory cytokines (TNF-a and TGF-b)
diffuse through the tissues adjacent to the site of their initial
release. When the local concentration of TGF-b reaches a certain
threshold, SMC and EC proliferation in that area will be triggered
[35,36]. When the local concentration of TNF-a reaches a given
threshold, SMCs and ECs apoptosis will be triggered [37]. This
simplified description of the in vivo interactions among the major
cell types and cytokines of interest in the development of restenosis
is illustrated in Figure 1. In this figure, these cell types and
cytokines are color-coded to make it consistent with the colors of
agents used in the model.
It is important to note that the in vivo interactions are much
more complicated than this simplified description. For instance,
TGF-b can act as both a pro- and anti-inflammatory cytokine at
different stages of restenosis development [38,39]. There are also
many other cytokines and growth factors (e.g., interleukin 8,
interleukin 6, platelet-derived growth factor, fibroblast growth
factor, vascular endothelial growth factor, etc.) involved in the
whole process [40]. In this model, TGF-b and TNF-a were used to
represent anti-inflammatory cytokines and pro-inflammatory
cytokines, respectively. The use of only a few cytokines in agent-
based models of inflammatory-based healing responses is a
frequently applied practice [41,42]. This simplification is necessary
because the precise roles of these cytokines within the complex
in vivo environment are not clear while the presence of anti-
inflammatory and pro-inflammatory cytokines are vital to the
dynamic interactions among the major contributors to restenosis
development [5,40]. The major purpose of this work is to simulate
the dynamic interactions among these major contributors and to
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PLOS ONE | www.plosone.org 2 April 2014 | Volume 9 | Issue 4 | e94411
determine their roles in the development of restenosis. Without
proper simplification, this model with detailed interactions among
a large number of cytokines and growth factors would not produce
any meaningful results.
B. Model Construction
i) Settings of the model. Corresponding to the structure of
the coronary artery, the agent-based model developed in this work
contains four major compartments in a simulated arterial cross-
section: the lumen, intima or neointima layer (endothelial cells
and some smooth muscle cells), the media layer (mainly smooth
muscle cells), and the adventitia layer. The model also includes
agents representing platelets, monocytes, neutrophils, and macro-
phages, along with cytokines such as TNF-a and TGF-b.
The environment of interest in the model is the treated blood
vessel post-implantation of the stent. The simulated environment is
a two-dimensional cross-section of the treated blood vessel.
Although three-dimensional agent-based models can also be
created, the use of a two-dimensional model is supported by the
prevalence of the use of two-dimensional cross-sections in assessing
vulnerable atherosclerotic plaques [43]. The cross-section with the
smallest lumen diameter is the limiting factor for blood flow and is
thus the case of greatest interest. The simulated results from this
two-dimensional model can also be directly compared with those
obtained in published serial angiography or ultrasound studies.
The agent-based model is created on a 1506150 grid, which
corresponds to 22,500 square patches in total. All the agents in the
model are contained on these patches in the grid. In the NetLogo
program, one distance unit is defined as the distance between the
centers of two adjacent patches in the grid, which is also the side
length of a patch. In this model, one distance unit represents
0.05 mm in vivo. The size of a patch is also used as a reference for
agent sizes. For instance, if the size of an agent is 1.0 unit, the
agent’s diameter (for a circular agent) or side length (for a square
agent) is the same as that of a patch side.
In this model, one time step represents 6 hours. In the agent-
based model, each agent’s behavior follows a list of behavioral rules
(Table 1). These behavioral rules are implemented as functions in
the model within the NetLogo platform. When the agent-based
model is running, in each time step the model checks the agents’
current situation and determines which function(s) should be
executed and what input values should be utilized. If the current
value of a variable is needed by a function, the model assesses the
corresponding local environment to determine the correct value to
use. Here an agent’s local environment is defined as the patch with the
desired agent on it, and its 8 immediately adjacent patches in the
grid space (illustrated in Figure S1 in Text S1). For instance, if a
Figure 1. An interaction diagram for cells and cytokines represented in the model. The major players in the interaction are shown in boxes
with colors. These colors are the same as the ones used in the visual output of the agent-based model. The solid green lines mean something is
releasing and the dashed lines mean an event is being triggered. Here is the color code for events: light-green for proliferation, light-blue for
recruitment, red for activation, and black for apoptosis. The numbers in the diagram indicate the order of those events at the beginning of a model
simulation.
doi:10.1371/journal.pone.0094411.g001
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function requires the local TGF-b concentration, the model will
count the number of TGF-b agents on the patches in the local
environment and calculate the concentration value accordingly
(counts/volume).
An agent-based model is advantageous in that the number of
each type of agent can be tracked continuously in one run of a
simulation. All these numbers of agents in different types are
discrete values obtained by counting each type of agent on all the
patches in the grid. In some cases, the numbers of agents
themselves are sufficient for providing the desired information, for
instance, the populations of ECs and SMCs. In other cases, these
numbers of agents need to be compared with values reported in
the literature, for instance, the concentrations of TNF-a and TGF-
b. In the latter situation, the number of agents in the model
collected during a simulation is converted to a value with the same
unit as the ones measured in experiments. This conversion
mechanism is set up when the model is initially constructed and is
not changed in any subsequent simulations.
In the model, the coronary artery cross-section environment is
populated by multiple types of agents. Some of these agents are
initially bound to a specific location in the grid space and some of
them freely circulate in the lumen. The agents initially assigned to
a specific location are based on the in vivo makeup of the vessel wall
layers. The intimal layer is chiefly populated by a small number of
SMC agents and EC agents, representing the endothelial
monolayer. The medial and adventitial layers are populated
entirely by SMC agents. The other agent types present in the
model prior to simulation initiation are platelet agents, latent
TGF-b agents, plaque agents, and stent strut agents. Stent strut
agents (representing the struts in a bare-metal stent) are evenly
placed around the initial lumen boundary and remain unchanged
during the course of a simulation. Illustrations from Thim et al.
were consulted during the creation of the visual environment of
the model prior to the start of a simulation [14]. The plaque size
and location are set prior to simulation initiation and are
maintained throughout the simulation. Once a simulation starts,
other types of agents, such as monocytes, neutrophils, macro-
phages, appear in the model in accordance with the behavioral
rules described in the following section.
ii) Behavioral rules of agents in the model. In an agent-
based model, the behaviors of agents are controlled by type-
specific rules. In this model, the agents’ behavioral rules control
replication rates, responses to the presence of other agents, and
interactions of agents with their environment. In certain cases, the
type of agent can be changed and consequently, the corresponding
behavioral rules of the new type would be applied to the agent.
This transition is typically based on the agent’s position, type, and
the local environment. One example of an agent type reassign-
ment is the transformation from latent platelets to activated
platelets. When circulating latent platelets encounter the wound
site, their agent type is changed to activated platelet to reflect the
activation event that would take place in vivo. In the model, latent
platelets and activated platelets are distinct agent types and they
are associated with different colors, sizes, and behavioral rules.
The behavioral rules for agents in the model are compiled
according to an extensive literature survey and are summarized in
Table 1. A list of simplified rules of agents in the model.
Agent Interaction rules
Platelets Latent platelets move randomly in the lumen.
When latent platelets meet injury sites or activated platelets, they are activated.
Activated platelets aggregate together and lead to thrombus formation.
Platelets die when they reach their given life-span.
TGF-b Representing anti-inflammatory cytokines
Activated platelets, SMCs, and ECs release TGF-b.
A greater injury site triggers an increased release of TGF-b.
A change in lumen area affects the release rate of TGF-b.
Recruiting monocytes and neutrophils
If the local concentration of TGF-b goes beyond a threshold, SMCs and ECs proliferation will be triggered.
TNF-a Representing pro-inflammatory cytokines
Monocytes, neutrophils, and macrophages release TNF-a in the same rate, and the release is triggered by a TGF-b gradient.
If the local concentration of TNF-a goes beyond a threshold, SMCs and ECs apoptosis will be triggered.
Monocytes, neutrophils,
macrophages
When the local TGF-b concentration in the intimal layer exceeds the femtomolar level, circulating neutrophil and monocytes
appear in the lumen.
The migration rate of these monocytes, neutrophils, and macrophages is 1mm/min. During the migration, if neutrophils meet
activated platelets, neutrophils attach to the thrombus.
Monocytes move through the thrombus and change into mature macrophages.
Some macrophages stay with stent struts and simulate a foreign body response. Other macrophages are elsewhere and trigger
typical inflammatory actions.
SMCs Injured intimal SMCs replicate twice every proliferation cycle.
Proliferating medial SMCs can migrate to the intimal layer and change to intimal SMCs.
Each patch in the grid can only hold 15 SMC agents. Once this limit is reached, the extra SMCs are pushed to neighborhood
patches in the direction of the lumen.
ECs ECs always reside on patches adjacent and interior to the forward-most patches holding SMCs. When SMCs move toward the
lumen, ECs move accordingly.
doi:10.1371/journal.pone.0094411.t001
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a list form in Table 1. These rules have been simplified in order
that they may be presented in the table. Further explanation of
these rules and the corresponding supporting evidence are
provided in Text S1.
iii) Parameters. The second main component of an agent-
based model is the parameters associated with different types of
agents. In this model, the parameters that are associated with the
different cell types were set to the correct relative proportions
based on data from the literature. Each agent is associated with
multiple parameters that govern its behavior. The size and color of
each agent were selected so that the simulation output is similar to
a real situation and easy to understand. The parameters for each
agent type in the model are presented in Table 2. Further details
about how these parameters were chosen and implemented in the
model are explained in Text S1.
C. Model Interface, Outputs, and Parameter Sensitivity
i) Modifiable parameters in the model interface. The
model interface consists of modifiable parameters and quantitative
and visual outputs. These modifiable input parameters include the
lumen diameter (in mm) following angioplasty and stent implan-
tation, the stent length (in mm), the number of stents, and the
arrangement of the stent struts in the vessel cross-section. All of
these parameters have default values. Prior to the initiation of the
model in each simulation, these parameters can be set to desired
values according to the purpose of the simulation.
Some input parameters were incorporated into the model due
to the increasing interest in overlapping-stent cases and the effects
of novel stent designs. Parameters specifically relevant to these
topics are the number of stents in the simulated cross-section, the
number of struts per stent, and the spacing of the stent struts, all of
which can be manipulated in the model interface. When
simulating an overlapping-stent scenario, the same input param-
eters are applied to both stents. In the model interface, there are
two options for the two stent strut arrangement: aligned and
staggered. In the aligned arrangement, the struts of the interior
stent are placed right above the ones of the exterior stent. In the
staggered placement, each of the struts on the interior stent is
placed at the center of two adjacent struts on the exterior stent.
For both single- and multi-stent simulations, the size of the stent
struts and either the number of stent struts or the spacing between
two adjacent struts (in mm) can be set at the beginning of the
simulations. The default stent strut size is 0.1 mm [44], and the
default number of struts per stent is 20 in the vessel cross section
[45,46]. For any designated number of struts in the stent(s), those
struts are always evenly spaced around the post-stenting boundary
of the lumen. For any given spacing between two adjacent struts,
an appropriate number of struts is determined by dividing the
post-stenting lumen circumference by the selected spacing and
rounding to the nearest integer value.
An additional modifiable parameter is the vessel wall thickness.
This parameter does not appear in the model interface, but its
value is calculated based on the initial lumen diameter. Since the
vessel thickness is typically not reported in experimental studies, in
this model the default wall thickness is defined as being equal to
the given lumen radius, based on the observation that the typical
ratio between the lumen radius and the vessel wall is roughly 1:1
[47].
ii) Simulation outputs: value measurement
protocols. The agent-based model can produce both numerical
and visual outputs in the user interface. The quantitative outputs
are the final lumen diameter, the days to reach a stable lumen
diameter (the time to lumen diameter stabilization), the percent
change in lumen area, and the local and serum concentrations of
TGF-b and TNF-a (both in ng/ml, or nanogram/milliliter, or
1026 kg/m3). In this model, one of the visual outputs is a plot that
tracks the population of SMC and EC agents during a simulation.
The other visual output is a color-coordinated diagram of the
blood vessel cross-section, which is continuously updated during
each simulation to illustrate the positions of different types of
agents in the model and the changes to the lumen area. In this
model, a few variable measurement protocols were implemented
to obtain the information for all these valuable outputs.
Table 2. Summary of parameter values governing release rates, cytokine sensitivities, migration rates, proliferation rates, color,
size, and lifespans of agents in the model.
Agent (color, size) Parameter Parameter Value of Reference Source
TGF-b (invisible, 0.0002) Release rate 0.02 pg/10 hours/cell [74]
TNF-a (invisible, 0.0002) Release rate 0.02 pg/10 hours/cell [74]
SMCs (green, 0.6) TGF-b sensitivity 3 ng/ml [49]
Migration rate 20 mm/hour [75]
Proliferation rate Population doubles every 30 hours [76]
Monocytes, neutrophils, and macrophages TGF-b sensitivity 1 fmole [28]
ECs (pink, 0.42) and SMCs TNF-a sensitivity 4 ng/ml [37]
Maximum apoptosis rate following TNF-a exposure 15% of the population [77]
Platelets (red, activated: 0.4, latent: 0.3) Lifespan 5–10 days [78]
Monocytes (blue, 0.54) Migration rate 1 mm/min [79]
Lifespan 3 days [80]
Macrophages (cyan, 0.54) Lifespan 45 days [81]
Neutrophils (light blue, 0.54) Lifespan 5 days [82]
Stent struts (gray, 2.7) Default size 0.1 mm [44]
Default number of struts per stent 20 [45,46]
Plaque (violet, 0.7) Lifespan No limit
doi:10.1371/journal.pone.0094411.t002
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To measure the changes in the lumen cross-sectional area, the
model used the location of intimal EC agents as the reference
points for the boundary of the new lumen. This lumen diameter
measurement method was utilized to ensure that the model
monitors the worst-case lumen obstruction, which is considered to
be most clinically significant. Consequently, percent change in
lumen area was calculated according to the equation below:
DS~
Li{L2
L2
|100
where DS is the percent change in lumen area, Li is the initial
lumen area (in mm2) prior to the start of a simulation and L2 is the
new lumen area (in mm2) based on the minimum lumen diameter
(in mm).
In the numerical outputs of the model, the concentrations of
TGF-b and TNF-a are reported as values comparable to the ones
reported in the literature (in ng/ml). The local cytokine
concentrations are calculated by counting the numbers of these
cytokine agents on a patch of interest and its adjacent 8 patches
(the local environment), and then dividing this count by the
volume for the chosen patch set. For any patch of interest, the
corresponding volume of the local environment is defined as
V=C6AP, where V is the volume, C is a constant for the
thickness of the patch, and AP is the area of 9 patches. In the
numerical output in the model interface, the reported cytokine
concentrations include both the local and serum concentrations of
the cytokines. The local cytokine concentrations directly affect the
proliferative and apoptotic behavior of those cell agents within the
measurement perimeter according to the behavioral rules. The
serum concentration of the cytokines does not affect the behavior
of any cells in the model but rather serves as a checkpoint to
ensure that the net cytokine release does not exceed normal
physiological ranges. Acceptable serum TNF-a values were
determined to be between 0 and 10 ng/ml, based on in vivo
studies [37], and the same range was considered to be acceptable
for the serum TGF-b concentrations [48,49].
The model constantly reports the simulated days post-interven-
tion in the model interface. In each simulation, the number of days
from the beginning of the simulation to the end of TGF-b release
is used as the lumen diameter stabilization time (in days). After this
point, data are recorded for an additional 60 simulated days to
confirm that the lumen diameter had become static.
iii) Simulation outputs: examples of visual lumen area
changes. The visual outputs for the blood vessel cross-section
from both single-stent and overlap-stent simulations using the
initial parameters from [50] are shown in Figures 2A–2H. These
visual outputs were randomly selected from simulations.
Figures 2A–2F are the results from single-stent simulations while
Figures 2G and 2H are the results from an overlapping-stent
simulation. Figures 2A–2D are all from one individual simulation
while Figures 2E–2G are from different simulations. Figure 2A
illustrates the initial setting of the vessel cross-section right after the
initiation of the simulation, which represents the status of the vessel
immediately following the angioplasty and stent implantation
procedure. Visible agents at this stage include platelets (red) in the
lumen, stent struts (gray squares), ECs (pink), SMCs (green), and
plaque (violet, bottom-left corner). Figure 2B presents the vessel
cross-section 15 simulated days after the stent procedure.
Monocytes (blue), neutrophils (light blue), and macrophages (cyan)
were present in the model by this time point. The population of
SMC agents (green) increased significantly during the 15 days.
Figure 2C shows the status of the blood vessel 59 days after the
procedure. Figure 2C clearly reflects the proliferation of EC and
SMC agents and migration of SMC agents towards the lumen.
Figure 2D illustrates the ultimate results of this simulation. The
lumen diameter was stable after 84 simulated days and 45.52% of
the original lumen area was occupied by the neointima. In this
particular case, the neointima did become thicker, however, it did
not reach the point of restenosis (greater than 50% lumen area loss
[51]). In other simulations, the SMCs and ECs keep proliferating
and migrating towards the lumen. The neointima may then
occupy a large portion of the lumen ($50% of the lumen area).
This phenomenon is demonstrated in Figure 2E, which is the
result from a different simulation from Figure 2D. The lumen was
stabilized after 88 days and the neointima occupied 77.67% of the
original lumen area. The result depicted in Figure 2F, which is
from yet another separate simulation, represents the worst-case
result. In this instance, the neointima advanced to such an extent
that it occupied the entirety of the lumen space, which occurred 69
days after the intervention. In the cases of both Figures 2E and 2F,
restenosis would have been developed in the simulated artery since
the neointima occupied more than 50% of the original lumen
area. Figures 2G and 2H display the initial setting and the final
result of an overlapping-stent simulation, respectively. A staggered
stent strut arrangement was selected for this simulation, which is
illustrated in Figure 2G.
iv) Parameter sensitivity analysis. The purpose of the
parameter sensitivity analysis was to identify any parameters for
which a small change in the parameter value resulted in a significant
alteration in the behavior of the model. Sometimes, the model’s
sensitivity to a particular parameter does not have an obvious
connection to in vivo events based on the literature. The sensitivity
analysis was also meant to check the reasonableness of the model results
when small perturbations were made to model parameters. Any
physiologically impossible or implausible results stemming from
minor alterations to model parameters would highlight a potential
weakness in the model construction. As exhibited by the results of
the sensitivity analysis, no such weaknesses were identified during
the course of the testing on this model.
A few hundred simulations were performed to confirm the
consistency of the simulation results. No irregularities (i.e., a
simulation reaching completion within a timeframe of only a few
simulated days, dramatic/unexpected changes of simulated
behavior in the middle of a simulation, or failure to reach lumen
diameter stabilization, etc.) were observed in these test simulations.
For each given set of initial parameters, the final lumen diameters
obtained from those simulations were consistent. A simple test was
conducted using one set of input parameters to demonstrate the
consistency of the results. The test procedure and results are
presented in Text S1. This simple test indicates that the average
values of two groups with the same input parameters and 10
random runs are highly consistent. Therefore, it is sufficient to
have 10 runs per simulation for data reporting. In the rest of this
article, all of the reported results are the average values of 10
random runs of the simulation with the indicated parameters.
The results of the sensitivity analysis for functions with direct
physiological meaning are presented in Tables S1 and S2 in Text
S1. After all simulations for one alteration were completed, the
model was run in its normal configuration for two simulations to
confirm all changes had been reversed prior to performing the
next alteration. The results presented in Tables S1 and S2 in Text
S1 indicate that the model is extremely sensitive to functions
related to intimal and medial apoptosis and proliferation,
inflammatory cell adherence and migration, and TNF-a. The
influence of intimal and medial apoptosis and proliferation
functions on the final results of the model is expected based on
the in vivo pathogenesis of restenosis, and the significance of the
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inflammatory cells (monocytes, neutrophils, and macrophages in
this model) is because they release cytokines in their local
environment. The adventitial SMCs’ apoptotic and proliferative
functions do not have a significant impact on model outcomes
because adventitial SMCs do not migrate to other layers of the
vessel wall and thus changes in the adventitial SMC population do
not contribute to the development of neointima. As noted in Table
S2 in Text S1, the endothelial proliferation functions do not
contribute to increases in neointima thickness due to the single
layer feature of ECs in the neointima layer. The locations of ECs
are, however, crucial to the measurement of the lumen diameter.
D. Model Validation and Overlapping-stent Simulation
Procedures
The goal of the model validation testing was to assess the
integrity of the model’s quantitative outputs. To this end,
simulations were performed using vessel parameters from three
serial imaging studies [50,52,53]. These three imaging studies were
selected specifically because these studies reported both initial and
final lumen diameters and had extended follow-up times and high
participant retention rates. For each comparison, 10 runs of each
simulation were performed with the parameters of the corre-
sponding imaging study as the input parameters of the model. The
average final lumen diameter and average time to lumen diameter
stabilization (6 standard deviation) from these 10 runs of each
simulation were then reported. The time to lumen diameter
stabilization was rounded to the nearest day. The outer diameters
of the imaged vessels were not given in any of these three imaging
studies, and therefore the default vessel thickness (the same as the
given lumen radius) was used in these simulations.
The plaque in the model was placed at the bottom left corner of
the simulated cross section across all simulations. Because the
vessel’s cross-section is a circle, repositioning the plaque along the
circumference should not affect the simulation results. The plaque
size in the model was also preset at a specific value, described by
four boundary values (x1, x2, y1, y2). The location and size of the
plaque can be manipulated by modifying these four boundary
values within the code of the model. However, because there was
no information about the position and size of the plaque in the
targeted vessels imaged in the comparison studies, the plaque
location and size were maintained at the model’s default
configuration. If the location and size of the plaque need to be
changed, the new boundary of the plaque should not protrude into
the lumen or distort the stent. This is required by the innate
assumption that the blood vessel’s cross-section is a circle after the
angioplasty and stenting procedure. In all other respects, the
consequences of plaque rupture should be taken into account in
the model. As indicated at the beginning of the Materials and
Methods section, this model does not incorporate the contribution
of a ruptured plaque to the inflammatory reactions in the process
of restenosis development.
For the overlapping-stent simulations, the expected result was
an increase in lumen cross-sectional area loss as a consequence of
the increased vessel wall damage inflicted by the second set of stent
struts and the corresponding increased intimal hyperplasia [10].
Overlapping-stent simulations were run using the initial post-
implantation vessel parameters from Kimura et al. [50]. This study
was chosen after the completion of the model validation
simulations due to the closeness of the model’s results with the
results reported in the comparison study. Ten runs of each
overlapping-stent simulation were conducted to make sure that the
obtained results were stable.
Figure 2. Visual outputs from single-stent and overlapping-stent simulations. Simulations utilized the initial vessel parameters from Kimura
et al. [50]. 2A–2D: Snapshots from a single-stent simulation at different days (days 0, 15, 59, and 84). 2E–2F: Final results from two single-stent
simulations with different levels of restenosis. 2G–2H: The initial and final images from one overlapping-stent simulation.
doi:10.1371/journal.pone.0094411.g002
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Results
A. Single-stent Simulations for Model Validation
i) Final lumen diameter. The average final lumen diameter
and the average time to lumen diameter stabilization for each
comparison simulation are given in Table 3. Across all three sets of
validation simulations, the average values of the final lumen
diameters generated by the model were all within one standard
deviation of the means reported in the corresponding serial
imaging studies from which the input model parameters were
taken. The results from the simulation using the parameters from
Chamie´ et al. differed more from the reported mean diameter than
the results for the other two sets of simulations [52]. This
discrepancy is likely due to the size of the vessels investigated in the
Chamie´ et al study. Chamie´ et al specifically evaluated stent
patency in smaller vessels. A smaller diameter atherosclerotic
blood vessel may undergo stress-induced remodeling, resulting in a
different lumen radius to vessel wall thickness ratio [54]. However,
because no vessel wall thickness values were reported in the study
by Chamie´ et al., the validation simulations were conducted with
the default 1:1 ratio between lumen radius and vessel wall
thickness. If accurate values of vessel thickness were available, the
accuracy of the model predictions would likely increase.
ii) Time to lumen diameter stabilization. The average
time to lumen diameter stabilization from the model validation
testing is also presented in Table 3. The time to lumen diameter
stabilization generated by the model paralleled the study follow-up
times for all three studies, in spite of the inter-study variation in
follow-up periods. It is pertinent to note, however, that these
investigator-determined follow-up periods may not reflect the
actual time needed for lumen diameter stabilization in vivo.
iii) Percent change in lumen area. Due to wide variations
in the method of calculation for percent change in lumen cross-
sectional area reported in the literature, the values of percent
change in lumen area from the model were not compared with the
values reported in the literature. Instead, the average percent
change in lumen area over time generated from model simulations
was compared across the three sets of validation simulations.
Figure 3 displays the simulated percent change in lumen area over
time.
While the initial parameters, final lumen diameter, and time to
lumen diameter stabilization varied according to input parameters,
the curves in Figure 3 show that the percent change in lumen
diameter followed the same trajectory across all three sets of
simulations from simulation initiation to lumen diameter stabili-
zation. The consistent nature of these curves reflects consistent cell
and cytokine positive- and negative-feedback interactions across
simulations and reinforces the validity of the numerical results
presented in Table 3. If the path to lumen diameter stabilization
varied significantly when different input parameters were used, it
would indicate that the cell and cytokine interactions were not the
main effectors of the lumen diameter change over time and the
model results were artificially affected by the input parameters.
iv) Comparison of local cytokine levels. As discussed
earlier in the Materials and Methods section, the serum cytokine
concentration does not affect the behavior of any agents in the
model. The serum concentrations of TGF-b and TNF-a serve as a
checkpoint to ensure that the cytokine release does not exceed
normal physiological ranges. As noted earlier, TGF-b and TNF-a
concentrations are between 0 and 10 ng/ml. In all three sets of
validation simulations, the serum cytokine concentrations re-
mained within the normal range.
Local cytokine concentrations, however, are critically important
to the functionality of the model as the local cytokine concentra-
tions dictate the changes in the SMC and EC populations. For all
validation simulations, the local cytokine levels for both TGF-b
and TNF-a were within the expected ranges, which was the same
as the normal serum range defined above. The maximum local
TGF-b concentration experienced in the 30 runs of validation
simulations was approximately 6 ng/ml, and the maximum local
concentration for TNF-a was approximately 9 ng/ml.
B. Overlapping-stent Simulations
The average final lumen diameter for the overlapping-stent
simulations (using the Kimura et al. parameters [50]) was
1.796.02 mm2, and the average time to lumen diameter
stabilization was 11268 days. These results represent a 14.5%
decrease in average final lumen diameter and a 25.6% increase in
the average time to lumen diameter stabilization from the single
stent simulation results that used the same input parameters.
The overlapping-stent simulations exhibited an increase in
lumen area loss and in time to lumen diameter stabilization. Both
of these findings were expected based on the literature. The
increased damage to the vessel wall caused by the additional stent
resulted in increased apoptosis at the time of the intervention. The
increased cytokine release also recruited more inflammatory cells,
which released more TNF-a, requiring a prolonged vessel
recovery time. The increased damage also triggered a chain
reaction of increased cytokine release and subsequent increased
cell proliferation and migration, which created amplified intimal
hyperplasia. This reasonable explanation may indicate the
qualitative expectation based on the literature, however, it cannot
provide quantitative results when some specific input parameters
are given. The simulations conducted in this agent-based model
can provide the desired quantitative values.
C. Comparison between Single-stent and Overlapping-
stent Simulation Outcomes
i) Percent change in lumen area. Figure 4 presents the
average percent change in lumen area over time from the single-
stent simulations (solid line) and the overlapping-stent simulations
Table 3. Initial parameters and final results from serial imaging studies used for comparison by Kimura et al. [50], Hoffman et al.
[53], and Chamie´ et al. [52] and model final lumen diameter and time-to-stabilization results.
Comparison Study Measurement method
Study initial
LD* (mm)
Study final
LD (mm)
Study follow-up
time (months)
Model final
LD (mm)
Model time to LD
stabilization (days)
Kimura et al. Angiography 2.96.04 2.26.6 3–6 2.136.02 8967
Hoffman et al. Intravascular ultrasound 3.196.51 2.126.82 5.463.8 2.346.02 82616
Chamie´ et al. Intravascular ultrasound 2.396.13 1.286.74 7.261.0 1.756.05 93615
*LD= lumen diameter.
doi:10.1371/journal.pone.0094411.t003
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(dashed line). Both sets of simulations utilized the initial
parameters from Kimura et al. [50]. The differences between the
two curves in Figure 4 illustrate the effects of altered hyperplasia-
apoptosis balance. Although the trajectory of the overlapping-stent
simulation curve is similar to the results for the single-stent
simulations in Figure 3, the curve of the overlapping-stent
simulation (dashed line) exhibits a phase delay with respect to
the single-stent case (solid line). This delay is likely due to the
increase in initial levels of apoptotic cell death, caused by the
presence of the second stent. The lower initial SMC population in
the case of overlapping-stent likely contributed to the delayed re-
growth of the intima. However, the increased vessel wall injury
also triggered an increase in the number of cells releasing the anti-
inflammatory cytokine TGF-b. Thus, once the concentration of
TGF-b reached a certain level, the change in lumen diameter was
accelerated with respect to that in the single-stent simulation. This
is reflected in the slope and magnitude of the curve for
overlapping-stent simulations following the phase delay.
ii) Local cytokine concentrations. Overall, the concentra-
tions of local TNF-a and TGF-b were higher in the overlapping-
stent simulations than in the single-stent simulations. While the
TNF-a levels were only higher by approximately 1 ng/ml, the
increase in the TGF-b levels was more significant, .2 ng/ml,
which represents a 33% increase. Notably, neither increase in local
cytokine concentrations elevated the total concentrations beyond
the physiologically appropriate limit (#10 ng/ml).
The increased local cytokine concentrations seen in the
overlapping-stent simulations provide support for the proposed
mechanisms behind the differences between the single- and
overlapping-stent simulations. Specifically, the altered local
cytokine levels coincide with the changes seen in the lumen
diameter data and in the percent change in lumen diameter curve.
The increased TGF-b levels are a reflection of the increased
hyperplasia, and the increased TNF-a levels are due to the
increase in the number of recruited inflammatory cells (monocytes,
neutrophils, and macrophages) drawn to the wound sites by the
increased TGF-b levels.
iii) Cell population changes. One set of results for the
percent change in the SMC population and the EC population
over time from the single-stent and overlapping-stent simulations
utilizing the initial parameters from Kimura et al. [50] are plotted
in Figures 5 and 6, respectively.
The effects of the altered cytokine concentrations in the
overlapping-stent simulations are reflected mainly in the SMC
population. The SMC population curve for the overlapping-stent
simulation displays the same phase delay coupled with a slope and
magnitude increase seen in the percent change in lumen diameter
graph for the overlapping-stent simulations.
In contrast, the effects of the altered cytokine concentrations on
the EC population appear to predominantly affect the initial
population and did not significantly alter the rate or magnitude of
the subsequent population growth. This disparity in the behavior
of the SMC and EC populations is likely due to the reduced
aggregate population of ECs in the model compared to SMCs.
There are more than twice as many SMCs as there are ECs
present in the model by the time of lumen diameter stabilization in
a number of simulations, and the effects of the altered cytokine
levels were more readily apparent on the larger scale.
Discussion
By utilizing the developed behavioral rules and the vessel’s post-
intervention parameters, the agent-based model described in this
article successfully simulated the response of an atherosclerotic
blood vessel to an angioplasty and bare-metal stent deployment
procedure as described in the literature. In addition, the model
was capable of accurately simulating the effects of overlapping-
stent deployment.
Simulations with three sets of parameters from imaging studies
verified the correctness and robustness of the model. The reported
results indicate that the model can reproduce the results observed
in the serial imaging studies by using the input parameters
obtained from these studies. Based on these results, it is obvious
that this model can be used to perform simulations with different
input parameters and produce correct predictions without any
alterations to the model’s mechanisms. The reasonableness of the
percent change in lumen area and time for lumen stabilization
results obtained from these simulations clearly demonstrate the
accuracy of the model.
Figure 3. Percent change in lumen area in single-stent simulations from each set of validation simulations. Simulation using Kimura et
al. parameters = solid; Hoffman et al. parameters = dash-dot; Chamie´ et al. parameters = dashed.
doi:10.1371/journal.pone.0094411.g003
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The results from the overlapping-stent simulations can also be
used as a prediction of the in vivo response to multi-stent
deployment. In a clinical setting, rather than in experiments,
two overlapping stents would not be placed concurrently. The
second stent is usually implanted after the restenosis in the first
stent has developed to a serious stage. This is one limitation of the
model in overlapping-stent simulations.
In the simulation for lumen area change in the case of a single
stent implantation, the simulated time to lumen diameter
stabilization was similar across all three compared imaging studies
(Table 3). However, since the follow-up periods for the study were
predetermined by the respective investigators in those studies, they
may not reflect the actual time point at which the lumen diameter
was stabilized. In addition, the variability in the simulation time
course is constrained by the effects of using a default vessel
thickness and assumed uniformity of the cell behaviors in the
model.
All model parameters were based on values for human cells and
cytokines reported in the literature. However, the exact regulation
mechanism for many of these processes, including growth factor-
and injury-regulated cell proliferation, has yet to be fully
delineated. The necessary assumption was that the adopted model
parameters held true for all cells of a given type in the simulated
environment when, in fact, the behavior of cells in vivo is not
uniform. Induced randomness in the model functions and using
in vivo measurements for the vessel thickness would likely further
Figure 4. Comparison of percent change in lumen diameter in single-stent and overlapping-stent simulations. Single-stent
simulations = solid and overlapping-stent simulations = dashed, all simulations using parameters from Kimura et al. [50].
doi:10.1371/journal.pone.0094411.g004
Figure 5. Comparison of the time course of SMC population changes in single-stent and overlapping-stent simulations. Single-stent
simulations = solid and overlapping-stent simulations = dashed, all simulations using parameters from Kimura et al. [50].
doi:10.1371/journal.pone.0094411.g005
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increase the accuracy of the simulation. The use of different values
for vessel wall thickness would impact simulation results since the
subsequent alterations to the TGF-b release parameter is
influenced by hoop stress, which is directly related to the vessel
wall thickness and lumen radius (More details about hoop stress
and its effect on TGF-b release rate can be found in Text S1).
The limitations of the model stem from the nature of
computational modeling itself. The size constraints imposed on
the model by the computing power of the NetLogo modeling
environment negatively affected the scale the model could simulate
by limiting the total number of agents that could be tracked within
the simulation. While there are more powerful modeling
environments that would partially alleviate this problem, attempt-
ing to simulate all the cells present in even a small cross-sectional
area of a human blood vessel would be an unwieldy undertaking
for any computational modeling environment.
In addition, it is difficult to recreate the precise natural
variations seen in the behavior of cells and cytokines in the body.
For instance, it is known that TGF-b has different behavioral
patterns at different stages of disease development [38], and
subsequently varies in its impacts on the behavior of other cells
and cytokines. In the model, TGF-b was treated as a single-
modality cytokine. One motivation for this type of simplification
was that the properties of those cells and cytokines are not yet well-
understood by investigators in the field. Thus, in order to recreate
those variations seen in vivo, modelers would have to make many
assumptions which might be random in nature and lack
supporting evidence in the literature. The other motivation for
the chosen simplification was that there are a large number of cell
and cytokine types involved in the process of restenosis develop-
ment. Attempting to include all of these cells and cytokines in the
model would introduce a number of unknown or not-well-defined
parameters into the model. Simplifications are a critical compo-
nent in the construction of effective and rigorous models and can
help investigators to concentrate on a limited number of essential
components in the simulated system [55]. This approach may
sacrifice the power of simulating the subtle differences of different
cytokines but yield a much clearer understanding of the critical
components that lead to in-stent restenosis.
However, the model created with these simplifications is fully
capable of simulating the variations in cell and cytokine effects on
a larger scale. As mentioned earlier in the Materials and Methods
section, the visual outputs of multiple random model runs for
simulations with the same set of input parameters produced
different results. In some model simulation runs (roughly 40% of
all runs), there was neointima layer thickening, but it did not reach
the point of clinically-defined restenosis [51]. In other model runs,
in-stent restenosis developed at different severity levels. This result
reflects the variation seen in the clinical manifestation of in-stent
restenosis. It is estimated that the rate of restenosis occurrence in
patients who have undergone an angioplasty and stent procedure
in randomized trials ranges between 30–40% [56,57]. Other
studies, however, have reported incidence rates as high as 48.8%
[58] or even 60% [5]. This natural variation in restenosis rates as
described in the literature was recreated by the model on both the
tissue and organ scales.
There were some innate assumptions in the model construction
process that merit discussion. For instance, it was assumed that the
majority of cells in the neointimal layer were SMCs and their
proliferation and migration were the driving forces of the
renarrowing of the lumen, under the influence and regulation of
multiple other cells and cytokines. This assumption was supported
by the literature [59], although there are other known factors in
this process, such as extracellular matrix deposition and vessel
remodeling (or persistent change in vessel size) [60]. This model
clearly indicated that SMC proliferation and migration is the most
important driving force in the development of restenosis, as
extracellular matrix deposition and vessel remodeling were
ignored in the model, but the model still could simulate the
development of restenosis with high accuracy. The model’s results
do not signify that patients with higher SMC proliferation and
migration will develop restenosis faster or more severely because of
dynamic interactions among SMCs, other cells, and cytokines.
From a clinical perspective, however, controlling SMC prolifer-
ation and migration may be a possible way to impede the
Figure 6. Comparison of the time course of EC population changes in single-stent and overlapping-stent simulations. Single-stent
simulations = solid and overlapping-stent simulations = dashed, all simulations using parameters from Kimura et al. [50].
doi:10.1371/journal.pone.0094411.g006
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development of restenosis. This is the therapeutic approach that
drove the development of drug-eluting stents [59]. In that
approach, the proliferation of SMCs and ECs is inhibited by the
drug that coats on the drug-eluting stents. Unfortunately, such
stents are not completely successful in improving patient outcomes
because they are associated with other risks, such as late and very
late thrombosis [61,62].
As described previously in the Materials and Methods section,
the model can be dynamically manipulated in the model interface
by editing the values for parameters such as the vessel diameter,
number of struts, size of struts, length of stent, space of struts,
number of stents and stent alignment. Such manipulation has have
already been demonstrated in the validation simulations with three
sets of input parameters. This type of simulations is used to
simulate a group of patients in a similar situation. Therefore
variations are observed in those simulations. In the future, the
authors plan to integrate more patient-specific parameters into the
model interface, such as platelets, leucocytes, and cytokines counts;
the size of the targeted plaque; and vessel wall thickness. The
updated model would then be able to produce more patient-
specific results.
The motivation for not including plaque rupture and the
corresponding intense inflammatory reactions in this model were
explained at the beginning of the Materials and Methods section.
In the future, the role of plaque rupture could be taken into
account in an extended model. In such a model, anti-platelet and
anti-inflammatory drugs, lipid, and interferon-c would be intro-
duced as agents in the model. The size and location of plaque are
also important in this case and therefore would have to be taken
into account in the model as well. The ruptured plaque releases a
large number of inflammatory factors in a short period of time and
triggers the activation of a large number of platelets that
subsequently results in acute thrombosis [18]. Without proper
control, both the strong inflammatory reaction and the acute
thrombosis may lead to patient death. Therefore, simulating the
consequences of plaque rupture is a critically important research
question.
As mentioned in the Introduction section, the vast majority of
patients, approximately 92%, who received the PCI procedures
also underwent stent procedures simultaneously [3,63]. An
important reason for this practice is that the elastic recoil right
after balloon angioplasty can result in approximately 50% cross-
sectional area loss on average [64]. Simultaneous stent placement
is advantageous in that it can easily prevent elastic recoil from
occurring. Conversely, implanting a stent also introduces further
damage to the blood vessel. The model presented in this article
was specifically created to simulate the response of the vessel to the
concomitant angioplasty and stent procedures. However, since
there are no similar models with a similar setting for the PCI
procedure alone before this model, it can be problematic to
determine the precise contributions from the stent in the
development of in-stent restenosis. Accordingly, the result of this
model cannot precisely identify the contributions of the stent to the
lumen area loss when compared to the development of restenosis
following a balloon angioplasty procedure. Therefore, even though
the results obtained from the simulations in this model with
varying stent parameters would be able to provide useful
information for designing or testing different stents, a more
accurate conclusion could be drawn after conducting simulations
with a similar model where the consequence of angioplasty
procedure alone is simulated. In the future, we plan to create an
agent-based model to simulate the development of restenosis after
only a balloon angioplasty procedure. The comparison between
the results from these two models should be able to further clarify
the contribution of a stent to restenosis development.
As mentioned earlier in this section, the drugs that coat on drug-
eluting stents inhibit the proliferation of all types of cells in the
blood vessel and therefore inhibit the development of in-stent
restenosis. However, patients with a drug-eluting stent have to
undergo prolonged anti-platelet drug therapy because the damage
to the endothelial cell lining and the media layer during the
angioplasty and stent procedure can never be recovered, making
platelet activation and subsequent thrombus formation a constant
risk [65]. Because drug-eluting stents can effectively help patients
to avoid in-stent restenosis and there are cheap anti-platelet drugs,
for instance, aspirin [66], they have been widely used in recent
years [67]. However, anti-platelet drugs can become a heavy
burden for patients who do not respond well to the typical
pharmaceuticals and patients who need to take multiple types of
anti-platelet drugs to effectively avoid thrombosis [68,69].
In the future, we plan to create a model based on the setting of
the current model that is capable of simulating the consequences
of drug-eluting stent deployment. In that model, the proliferation
and migration of SMC will not be so important while anti-platelet
drugs will have an important role [70–73]. This drug-eluting stent
model may be used to investigate the consequences of novel
approaches and new technologies. For instance, the model would
be helpful in investigating the possible results when the release of
drug coated on the stent is delayed until the initial damage has
been given time to heal. Such a controlled drug-eluting technology
would be very promising because it would allow for inhibiting the
proliferation of SMCs and ECs without the risk of late thrombosis.
The model could provide critical information on the appropriate
drug release timing to achieve this balance.
Conclusions
The developed agent-based model represents a simulation of the
interplay between the major contributors in the development of
restenosis in a human atherosclerotic blood vessel after an
angioplasty and bare-metal stent deployment. The model simu-
lated the body’s response to the intervention and generated results
consistent with serial imaging of human subjects across multiple
studies. This model may serve as a tool to explore how different
vessel cross-sections or stent arrangements may advance or reduce
the development of restenosis in a blood vessel.
In the future, the authors will develop this model further to
include more patient-specific physiological parameters and inves-
tigate the effects of plaque rupture. The authors will also create
two parallel models, one for the angioplasty-only intervention and
the other for the implantation of drug-eluting stents.
The model can be accessed at http://cpath.him.pitt.edu/stent/
index.html.
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